Two additional formulations of oral and injection solutions of Dexamethasone have been added to the list of medicines which are not meant for parallel export from the UK.
The Department of Health and Social Care (DHSC) and the Medicines and Healthcare products Regulatory Agency (MHRA) have announced that two additional formulations include all strengths and the additional restrictions have already came into place from Tuesday (June 16).
This came immediately after a study involving the drug was been hailed as a major breakthrough in the fight against Covid-19.
